Boehringer-Ingelheim
Burning Rock, Boehringer Ingelheim Ink Master Service Agreement for Oncology Companion Diagnostics
The companies will focus initially on Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin, now being studied in a new Phase II trial in China.
Thermo Fisher Scientific, Boehringer Ingelheim Partner on Companion Dx for Lung Cancer
The firms will develop multiple NGS-based companion diagnostic tests based on the Oncomine Dx Express Test and Oncomine Dx Target Test.
Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug
The companies will develop the FoundationOne CDx test as a companion diagnostic for Boehringer Ingelheim's BI 907828 in the US, Japan, and EU.
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
Qiagen Gets FDA OK for Expanded Use of EGFR CDx for Lung Cancer Drug
An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.